Literature DB >> 6305446

Partial myeloperoxidase deficiency in preleukemia.

P Cech, M Markert, L H Perrin.   

Abstract

In seven subjects with partial and apparently acquired form of myeloperoxidase (MPO) deficiency, some functional properties of neutrophils (PMNs) were studied. Five patients suffered from preleukemia, one from diabetes mellitus and one from carcinoma of the breast with bone marrow metastases. Intracellular bactericidal activity, oxygen consumption and superoxide radical production were within normal limits. In three patients with preleukemia, the serum opsonic activity was markedly reduced (less than m-3SD) in an autologous system, but normal in the presence of pooled normal serum. Decreased opsonic activity was also found when these patient's sera were assayed in the presence of normal PMNs. Since the levels of IgG and C3 were comparable in the patients' sera and the pooled serum, a deficiency of another unknown opsonin or the presence of an opsonization inhibitor has to be postulated. The partial MPO defect apparently doesn't decrease the intracellular killing of Staphylococcus aureus by PMNs. The known susceptibility to bacterial infections in preleukemia may be explained by the reduction of serum opsonization conducing to a secondary decrease of the ingestion and killing of bacteria by the PMNs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305446     DOI: 10.1007/bf00321047

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  29 in total

1.  Leucocyte energy metabolism. VI. Simultaneous and improved isolation of lymphocytes and polymorphonuclear leucocytes from a single of human blood.

Authors:  P Nessi; J Frei
Journal:  Enzyme       Date:  1977

2.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

3.  [Familial peroxidase-deficiency and acute myeloic leukemia (author's transl)].

Authors:  D Hunh; B H Belohradsky; R Haas
Journal:  Acta Haematol       Date:  1978       Impact factor: 2.195

4.  Cytochemical and ultrastructural studies of aberrant granules in the neutrophils of two patients with myeloperoxidase deficiency during a preleukemic state: relationship to abnormal bactericidal activity.

Authors:  J Breton-Gorius; Y Coquin; J L Vilde; B Dreyfus
Journal:  Nouv Rev Fr Hematol Blood Cells       Date:  1976

5.  Preleukemic states. I. Definition and classification. II. Refractory anemia with an excess of myeloblasts in the bone marrow (smoldering acute leukemia).

Authors:  B Dreyfus
Journal:  Nouv Rev Fr Hematol Blood Cells       Date:  1976

6.  Partial myeloperoxidase deficiency.

Authors:  P Cech; P Schneider; F Bachmann
Journal:  Acta Haematol       Date:  1982       Impact factor: 2.195

7.  New approaches to the detection of myeloperoxidase deficiency.

Authors:  P Dri; R Cramer; M R Soranzo; A Comin; V Miotti; P Patriarca
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

8.  Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection.

Authors:  R I Lehrer; M J Cline
Journal:  J Clin Invest       Date:  1969-08       Impact factor: 14.808

9.  Hereditary myeloperoxidase deficiency.

Authors:  M Kitahara; H J Eyre; Y Simonian; C L Atkin; S J Hasstedt
Journal:  Blood       Date:  1981-05       Impact factor: 22.113

10.  Function of neutrophils in preleukaemia.

Authors:  P Ruutu; T Ruutu; P Vuopio; T U Kosunen; A de la Chapelle
Journal:  Scand J Haematol       Date:  1977-04
View more
  2 in total

Review 1.  Myeloperoxidase: a front-line defender against phagocytosed microorganisms.

Authors:  Seymour J Klebanoff; Anthony J Kettle; Henry Rosen; Christine C Winterbourn; William M Nauseef
Journal:  J Leukoc Biol       Date:  2012-10-11       Impact factor: 4.962

2.  Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome.

Authors:  Y Itoh; T Kuratsuji; S Aizawa; M Sai; K Ohyashiki; K Toyama
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.